治疗偏头痛的创新药物——降钙素基因相关肽抑制剂erenumab

治疗偏头痛的创新药物——降钙素基因相关肽抑制剂erenumab

郎丰山,隋忠国,许鹏飞

临朐县人民医院药剂科,青岛大学医学院附属医院药学部,临朐县人民医院药剂科

收稿日期:2018-06-28 修回日期:2018-08-22 出版日期:2018-08-25

Erenumab as Calcitonin Gene-related Peptide Inhibitor for the Treatment of Migraine

LANG Fengshan,SUI Zhongguo and XU Pengfei

Linqu County People''s Hospital,Department of pharmacy, the affiliated Hospital of Qingdao University Medical College,Linqu County People''s Hospital

Received:2018-06-28 Revised:2018-08-22 Online:2018-08-25

摘要/Abstract

摘要： 降钙素基因相关肽（calcitonin gene related peptide，CGRP）受体近来成为治疗偏头痛的重要靶点，封闭CGRP受体能使CGRP失活。erenumab是目前唯一一个用于治疗偏头痛的单克隆抗体药物，能特异性地与CGRP受体结合，抑制降钙素基因相关肽所致的偏头痛。基于它在临床试验中的有效性和安全性，2018年5月美国食品和药品管理局（FDA）批准其上市。本文描述了它的基本信息、药理学、临床试验和安全评价，旨在为医生和患者提供有益的参考。

Abstract: Calcitonin gene related peptide (CGRP) has recently emerged as a promising target for migraine management. Functional blockade of the CGRP receptor inactivates CGRP. By now erenumab is the only human monoclonal antibody which specifically binds to CGRP receptor， thereby inhibiting CGRP-induced migraine. Based on the clinical efficacy and safety of erenumab， it has been approved by U.S. FDA in May 2018. An overview of erenumab including its general information， pharmacology， and safety value was presented in this article， to provide reference for doctors and patients.

郎丰山,隋忠国,许鹏飞. 治疗偏头痛的创新药物——降钙素基因相关肽抑制剂erenumab[J]. .

LANG Fengshan,SUI Zhongguo and XU Pengfei. Erenumab as Calcitonin Gene-related Peptide Inhibitor for the Treatment of Migraine[J]. .

参考文献

[1]Dodick DW. Migraine [J]. Lancet, 2018, 391(10127): 1315-1330.
[2]Silberstein, S. D. Emerging target-based paradigms to prevent and treat migraine [J]. Clin Pharmacol Ther, 2013, 93(1): 78-85.
[3]ManzoniSGC,SStovnerSLJ.SEpidemiologySofSheadache [J].SHandbSClinSNeurol,S2010, 97: 3-22S
[4] 张兵帅, 李博文, 邱智东,等. 偏头痛研究进展[J]. 亚太传统医药, 2017, 13(22): 43-45.
[5] 梁日楚.针刺治疗偏头痛临床疗效观察[J]. 中国医药导刊, 2011, 13(5): 775-777.
[6] 朱若绮, 王重新. 项六针配合平肝潜阳针法治疗无先兆偏头痛30例[J]. 湖南中医杂志, 2018, 34(7): 109-110.
[7] 冯霞, 刘玉静, 张若曦, 等. 活血通窍止痛汤治疗偏头痛临床疗效探讨与评价[J]. 河北中医药学报, 2015, 30(4): 16-18.
[8] 胡岩. 川芎茶调散对偏头痛患者头痛控制效果的影响[J]. 北方药学, 2018, 15(3): 123.
[9] 刘静, 郭珍, 李蕾, 等. 头痛宁胶囊治疗偏头痛的药效学研究[J]. 陕西中医药大学学报, 2018, 4(14): 96-100.
[10] 储新娟, 冯新格. 西比灵联合自拟中药汤剂治疗偏头痛36例疗效观察[J]. 中国医药导刊, 2015, 12(9): 1554-1556.
[11] 陶录岭, 袁　磊, 黄鹂丽, 等. 丹珍头痛胶囊联合盐酸氟桂利嗪治疗偏头痛的疗效及对血清5-HT、CGRP水平的影响[J]. 中西医结合心脑血管病杂志, 2018, 16(2): 1110-1113.
[12] 沈青, 杨先凯, 葛成芹, 等. 复方羊角片联合对乙酰氨基酚治疗偏头痛的临床研究[J]. 现代药物与临床, 2018, 33(5): 1038-1041.
[13] 王平. 加味血府逐瘀汤联合尼莫地平治疗偏头痛临床观察 [J]. 辽宁中医药大学学报[J]. 2016, 18(3): 180-183.
[14] Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache [J]. Ann Neurol, 1990, 28(2): 183–187.
[15] Schuster NM, Rapoport AM, et al. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review [J]. Clin Neuropharmacol, 2017, 40(4): 169-174.
[16] Reuter U. A review of monoclonal antibody therapies and other preventative treatments in migraine [J]. Headache, 2018, 58( Suppl 1): 48-59.
[17] Terwindt GM. Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment [J]. Genome Med, 2018, 10(1): 10.
[18] Israel H, Neeb L, Reuter U, et a. CGRP monoclonal antibodies for the preventative treatment of migraine [J]. Curr Pain Headache Rep, 2018, 22(5): 38.
[19] Raffaelli B, Reuter U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy [J]. Neurotherapeutics. 2018, 15(2): 324-335.
[20] FDA. Labels for Erenumab [EB/OL]. (2018-05-18)[2018-06-25]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761077s000lbl.pdf
[21] Shi L, Lehto SG, Zhu DXD, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor [J]. J Pharmacol Exp Ther, 2016, 356: 223-231.
[22] Vu T, Ma P, Chen JS, et al. Pharmacokinetic-pharmacodynamic relationship of erenumab (AMG 334) and capsaicin-induced dermal blood flow in healthy and migraine subjects[J]. Pharm Res, 2017, 34(9): 1784-1795.
[23] Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial [J]. Lancet Neurol, 2017, 16(6): 425-434.
[24] Dodick DW, Ashina M, Brandes JL, et al. ARISE: A phase 3 randomized trial of erenumab for episodic migraine [J]. Cephalalgia, 2018, 38(6): 1026-1037
[25] Goadsby, P.J., Reuter, U., Hallstrom, Y. et al. A controlled trial of erenumab for episodic migraine [J]. N Engl J Med 2017, 377(22): 2123-2132.
[26] Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial [J]. Lancet Neurol, 2016, 15(4): 382-390.
[27] Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial [J]. Lancet Neurol, 2014, 13(11): 1100-1107.
[28] Hong P, Wu X, Liu Y, et al. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis [J]. Clin Neurol Neurosurg, 2017, 154: 74-78.
[29] Li XW, Hu CP, Wu WH, et al. Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation:role of ERK1/2 and p27[J]. Eur J Pharmacol, 2012, 679(1-3): 117-126.
[30] Evangelista S. Role of calcitonin gene-related peptide in gastric mucosal defence and healing [J]. Curr Pharm Des, 2009, 15(30): 3571-3576.
[31] 尹优聪, 李元建. 降钙素基因相关肽介导的药物药理学效应 [J]. 中国药理学与毒理学杂志, 2017, 31(1): 112-117.

快速检索引用检索图表检索高级检索